Conclusions At the dose levels evaluated to date, JK08 has been well tolerated, demonstrating preliminary disease stability & anticipated modulation of target immune cell populations in aggressive heavily pre-treated solid tumors. These results provide an initial characterization of JK08 biology & activity.
over 1 year ago
P1/2 data • IO biomarker • Metastases
|
CD8 (cluster of differentiation 8) • IL15 (Interleukin 15)
Four tumor specific expansion cohorts will be initiated once dose and schedule are established from dose escalation and include melanoma, breast cancer, colorectal cancer, and a basket of advanced solid tumors. Response will be assessed every 9 weeks per RECIST v1.1.
over 1 year ago
Clinical • IO biomarker • Metastases
|
CD8 (cluster of differentiation 8) • IL15 (Interleukin 15)